Quick Facts

• Management of Viral Infections: May be used to help manage infections caused by the herpes simplex virus (HSV-1 and HSV-2), which can cause cold sores and genital lesions.
• Shingles and Chickenpox: May be prescribed for the treatment of herpes zoster (shingles) and varicella (chickenpox).
• Reduces Severity: May help decrease the severity and shorten the duration of symptomatic outbreaks.

---

What Cyclovid Treats: Main Uses and Benefits

Cyclovid is an antiviral medication that is a therapeutic option for addressing infections caused by certain types of herpesviruses, including herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus (VZV). The drug may be prescribed for the management of initial episodes and the long-term management of recurrent episodes of genital herpes. This therapeutic approach may help to reduce the formation of new lesions and promote the healing of existing sores during an outbreak.

In addition to genital herpes, Cyclovid is indicated for the acute treatment of herpes zoster (shingles) and for the treatment of varicella (chickenpox). The treatment may help to decrease the severity of symptoms associated with these viral infections. For patients who are immunocompromised, Cyclovid may also be used to manage certain limited, non-life-threatening mucocutaneous HSV infections. This medication functions by inhibiting the virus's ability to spread within the body, which can support improved patient outcomes. Cyclovid is not a cure for these viral infections, as the underlying virus may remain latent in the body.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Scope

The official eligibility profile for Cyclovid (Cyclophosphamide) defines the populations permitted for use, as well as several absolute contraindications and restrictions.

Eligibility Status	Applicable Populations
Approved for Use	Adult patients and pediatric patients across approved malignant and severe non-malignant indications.
Use is Contraindicated	Patients with a history of severe hypersensitivity to the drug or its metabolites, pre-existing severe bone marrow depression, urinary outflow obstruction, acute cystitis, and active acute infection.

Population Restrictions

Pregnancy and Lactation Eligibility: Cyclovid is contraindicated during pregnancy due to the risk of fetal harm. Use is also contraindicated during lactation, and breastfeeding must be discontinued during therapy.

Age and Organ Function:

• Geriatric Patients are advised to use with caution due to the higher likelihood of decreased organ function.
• Patients with severe renal or hepatic impairment require close monitoring for toxicity as mandated by regulatory labeling, classifying their use as conditional.

Official labeling defines non-eligibility based on clinical state and physiological status, ensuring use is confined to populations where the therapeutic context is warranted and regulatory restrictions are observed.

Cyclovid Interactions with other medicines and products

Cyclovid (cyclophosphamide) is a prodrug that requires activation primarily by the liver enzyme CYP2B6 (Cytochrome P450 2B6) and other CYP enzymes to form its active metabolites. This metabolic pathway is the basis for key pharmacokinetic interactions.

Drugs that inhibit CYP enzymes, such as certain azole antifungals (e.g., itraconazole, fluconazole), may alter the metabolism of Cyclovid, potentially leading to increased exposure to the parent compound and a change in the balance of active and inactive metabolites, which can increase the risk of toxicity. Conversely, agents that induce CYP enzymes (e.g., rifampicin) may increase Cyclovid metabolism.

Pharmacodynamic interactions often involve the potentiation of Cyclovid's inherent toxicities:

• Myelosuppressive Drugs: Concurrent use with other drugs that suppress bone marrow function (e.g., other antineoplastic agents) increases the risk of severe blood cell deficiencies, requiring close hematological monitoring.
• Cardiotoxic Agents: The risk of cardiotoxicity is increased when Cyclovid is given with other cardiotoxic medicines, such as Amiodarone.
• Anticoagulants: Co-administration with coumarin anticoagulants (e.g., warfarin) can enhance the anticoagulant effect and increase the risk of bleeding, necessitating regular monitoring of the International Normalized Ratio (INR).
• Live Vaccines: Due to its immunosuppressive effects, Cyclovid use is generally restricted in combination with live vaccines, which may pose a risk of infection or reduced vaccine efficacy.

Metabolic Activation to Active Metabolite

Cyclovid is a prodrug that requires metabolic activation. This transformation occurs predominantly through Cytochrome P450 enzymes in the liver, converting the parent compound into the resulting active cytotoxic metabolite, phosphoramide mustard. This biotransformation is the necessary initial molecular step that precedes the compound's systemic effects.

---

DNA Alkylation and Cross-linking

The active metabolite, phosphoramide mustard, acts as an alkylating agent that forms cross-links primarily at guanine bases on DNA strands. This modification disrupts the DNA structure, hindering both replication and transcription. This activity initiates signaling sequences that result in cell cycle arrest and induction of apoptosis.

---

Lymphocyte Proliferation and Pathway Adjustment

The drug engages mechanisms that influence cell cycle dynamics, specifically targeting proliferating immune cells. Its mechanism preferentially inhibits the proliferation of certain lymphocytes (immune cells). This action influences the proliferation rate of specific lymphocytes, thereby adjusting downstream signaling within immune pathways.

Official Administration Instructions for Cyclovid

The use of Cyclovid (cyclophosphamide) is strictly governed by prescribed regimens, which vary based on the patient's condition and weight, and are delivered by both Oral and Intravenous (IV) routes.

Dosing and Frequency

• Malignant Diseases (Adult and Pediatric): Dosing is patient-specific. IV regimens may involve 40 mg/kg to 50 mg/kg in divided doses over 2 to 5 days, or smaller doses administered every 7 to 10 days or twice weekly. Oral dosing is typically in the range of 1 mg/kg/day to 5 mg/kg/day for initial and maintenance treatment.
• Pediatric Minimal Change Nephrotic Syndrome: The oral dosage is 2 mg/kg once daily for 8 to 12 weeks, with a maximum cumulative dose of 168 mg/kg. Treatment is not recommended beyond 90 days due to increased risk of sterility in males.

Procedural Requirements

Administration Aspect	Administration Rule
Timing & Hydration	Administer the dose in the morning. Adequate fluid must be ingested or infused immediately before, during, or after administration to promote forced diuresis and reduce urinary tract risk.
Oral Preparation	Tablets must be swallowed whole and should not be chewed or crushed. Oral doses may be taken with or without food.
IV Preparation	The sterile powder for injection requires reconstitution. Aseptically dilute the reconstituted solution to the final concentration (e.g., 20 mg/mL for direct IV or 2 mg/mL for infusion) using approved diluents, such as 0.9% Sodium Chloride Injection, USP.
Injection Rate	The injection or infusion must be administered very slowly to mitigate the likelihood of administration rate-dependent adverse reactions.

If an oral dose is missed, take it as soon as possible, unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped. Do not double the dose. Any signs of urinary tract effects, such as blood in the urine, must be reported immediately.

Research Evidence / Overview of Studies for Cyclovid

Cyclovid was evaluated in various study types, including Randomized Controlled Trials (RCTs), Meta-analyses, and observational studies. These studies were designed to understand how the medicine was evaluated in complex, serious conditions, focusing on specific outcomes like survival and remission. The findings describe group patterns observed in the studies but do not provide individual predictions of response.

---

Evidence for Use in Malignant Diseases

Cyclovid was studied for its role, primarily in combination with other agents, in patients with conditions such as lymphomas, breast carcinoma, and ovarian adenocarcinoma. The research monitored endpoints, including Overall Survival (OS), Disease-Free Survival (DFS), Progression-Free Survival (PFS), and Clinical Outcome Measures. These studies describe patterns related to the outcomes of different patient groups over time when receiving specific combination protocols.

Research describes patterns related to the Clinical and Pathologic outcome measures that were monitored in patients utilizing established protocols. What is still uncertain is the contribution of its inclusion in certain specific combination regimens, as inconsistencies have been reported across some retrospective analyses.

---

Evidence for Use in Severe Autoimmune and Immunologic Conditions

Cyclovid was studied for its use in conditions involving periods of heightened symptoms, such as severe Systemic Lupus Erythematosus (SLE), specifically in patients with serious organ involvement like Lupus Nephritis. The research explored outcomes related to systemic or functional imbalance, including objective measures of Renal Response and standardized Disease Activity scores.

Findings describe patterns related to remission and maintenance of response in cohorts followed up to 30 months and longer. Research reports how symptoms evolved in the observed populations, summarizing the comparative data between different administration protocols. The evidence suggests that research is ongoing to provide comprehensive data directly comparing the long-term effectiveness of various administration protocols.

---

Evidence in Special Populations

Cyclovid was evaluated in specific special populations, particularly pediatric patients. For instance, it was observed in trials for certain types of solid tumors, as well as for the severe autoimmune condition Minimal Change Nephrotic Syndrome. Data for certain groups remain insufficient. Comparative evidence is lacking for some of these subgroups, meaning results apply only to the populations studied in the original trials.

Key Studies & References

1. Guidelines for the management of Nephrotic syndrome in children (Referencing use of Cyclophosphamide as second line therapy)
2. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis (Example of meta-analysis on malignant diseases)

Common questions about Cyclovid (FAQ)

Q: What is Cyclovid used for?

Cyclovid is an antiviral medication. It is primarily used to treat infections caused by certain viruses, such as herpes simplex virus (HSV), which causes cold sores and genital herpes, and varicella-zoster virus (VZV), which causes chickenpox and shingles. It works by interfering with the virus's ability to multiply.

---

Q: How does Cyclovid work in the body?

Cyclovid is a prodrug, which means it's initially inactive. Once taken, it is converted into its active form inside the body, mainly in cells infected by the virus. The active form then prevents the virus from copying its DNA, stopping it from spreading and replicating. This helps the immune system clear the infection.

---

Q: Is Cyclovid the same as an antibiotic?

No, Cyclovid is not an antibiotic. Antibiotics are specifically designed to treat bacterial infections. Cyclovid is an antiviral medication used to treat viral infections. It is not effective against bacteria, fungi, or other types of germs.

---

Q: What are some common side effects of Cyclovid?

Like many medications, Cyclovid can cause side effects. Common side effects can include headache, nausea, vomiting, and diarrhea. If any side effects are severe or persistent, you should discuss them with a healthcare professional.

Official Storage and Disposal Requirements

Official labeling requires Cyclovid to be stored at controlled room temperature, typically between 15 C and 25 C (59 F to 77 F). The product must be protected from moisture and light and should not be stored in high-humidity areas, such as the bathroom.

Keep the medication in its original container with the lid tightly closed to preserve stability. Always store Cyclovid and all medicines out of the reach and sight of children.

Disposal of unused or expired product should follow authorized methods, such as taking it to a drug take-back program. If the product is classified as a hazardous pharmaceutical waste, follow governmental and institutional protocols for proper disposal and environmental protection.